Tags : aMoon

BioTech

MiNA Therapeutics secures £23 million Series A investment led by

Funding, led by aMoon, will advance the clinical development of MiNA’s new class of RNA therapeutics for cancer treatment, and further expand its R&D pipeline in additional disease areas London, United Kingdom, September 10, 2020 – MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the completion of a £23 million ($30 million) Series A equity financing led by aMoon, Israel’s largest […]Read More